Navigation Links
Clarient Reports 2009 Third Quarter; Nine Month Results
Date:11/3/2009

a clearer picture of receivables, and help to improve future collections. And finally it will allow us to better forecast our future revenues, bad debts, profits and cash flows."

Land continued, "Taking into account these new estimates, we are now revising our revenue guidance for 2009 to $90 million to $94 million from the previous range of $96 million to $101 million. Even at the low end of the range, this will represent a year-over-year growth rate of greater than 22 percent from our 2008 revenues of $73.7 million."

Andrews concluded, "Clarient's business model built on a balanced revenue stream across multiple cancer types and technologies is well-positioned in the new environment of health reform and cost containment. The opportunities for Clarient to use its established commercial engine to bring new advanced tests to market are numerous and growing daily, and the greater predictability we now have will allow us to assertively pursue some exciting new opportunities while maintaining a focus on profitability and cash flow."

Conference Call

Clarient will hold a conference call to discuss third quarter 2009 results. The call will include a period for questions and answers.

Date: Tuesday, November 3, 2009

Time: 5:00 p.m. Eastern

Call-in Number: 1-888-549-7704 (domestic) 1-480-629-9857 (international)

Conference ID Number: 4177526

Webcast: www.clarientinc.com/investor

Web Replay: For those unable to participate during the live broadcast, a replay of the webcast will be archived at www.clarientinc.com/investor shortly after the call and will be available for one year.

About Clarient

Clarient combines innovative diagnostic technologies w
'/>"/>

SOURCE Clarient, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Clarient to Present at Noble Financials 5th Annual Equity Conference on Tuesday, June 9th
2. Clarient Completes Second Tranche of Private Placement of Convertible Preferred Stock With Oak Investment Partners
3. Clarient Granted Exclusive License to Commercialize Breast Cancer Biomarker by Indiana University Research and Technology Corporation
4. Clarient Reports Strong Revenue Increase for Fourth Quarter and Full-Year 2008
5. [video] Ronald Andrews, CEO of Clarient, Inc. Discusses Agreement With University of Pennsylvania School of Medicine on WallSt.nets 3-Minute Press Show
6. Clarient Names Raymond J. Land Senior Vice President and Chief Financial Officer
7. Jim Agnello to Resign as Clarient Chief Financial Officer
8. Clarient Announces Fourth Quarter and Year-End 2007 Financial Results
9. CombiMatrix and Clarient Collaborate to Market, Sell Novel Genomics-Based Test for Chronic Lymphotic Leukemia (CLL)
10. Clarient to Commercialize Novel Breast Cancer Profile
11. Clarient CEO Ron Andrews to Participate in OneMedPlace Emerging Healthcare Technologies Finance Forum
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... ... September 01, 2015 , ... Knowledgent , the ... the opportunities for advanced analytics utilizing data lakes in the healthcare industry. , As ... seen an explosion of data over the last few years as more entities become ...
(Date:9/1/2015)... ... September 01, 2015 , ... Research conducted by ... Angeles, Boston University School of Medicine, Frederick National Laboratory for Cancer Research, and ... first multidisciplinary Open Access journal. , Christopher Ryan PhD, of Synedgen, and ...
(Date:8/31/2015)... Aug. 31, 2015 /PRNewswire/ - BIOREM Inc. (TSXV: BRM) ("Biorem" ... million. The orders are for air emission abatement projects in ... is a large order for a municipality in the ... replacing a competitor,s system that failed to meet the customer,s ... solutions," said Derek S. Webb , President and Chief ...
(Date:8/31/2015)... -- Research and Markets ( http://www.researchandmarkets.com/research/k6lcp2/mexico_biomedical ) has announced ... - Growth, Trends & Forecasts (2014-2020)" report to ... Sensors market is estimated at $0.20 billion by 2018 ... The near future will bring biomedical sensors ... individual. These sensors can be set to trigger alerts ...
Breaking Biology Technology:New White Paper Explores Data Lake Opportunities in the Healthcare Industry 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 2Synedgen’s Director for Pharmaceutical Manufacturing Publishes New Research 3Mexico Biomedical Sensors Market Report 2015-2020 2
... 6, 2011 Van Andel Education Institute (VAEI) has ... to cooperatively recruit students interested in research training in ... genetic biology of human disease.    Under ... will work together to recruit qualified students at historically ...
...  Research Corporation for Science Advancement ( www.rescorp.org ), ... wholly to science, and the second-oldest overall (after ... its Honorary Centennial Observance Committee. The Committee, which ... 2012, is comprised of some of the most ...
... Inc. (Nasdaq: ECTE ), a company developing ... continuous glucose monitoring (tCGM) system and the Prelude® SkinPrep ... from its clinical study of its Symphony tCGM System ... Data from the study confirm that Symphony successfully monitors ...
Cached Biology Technology:Van Andel Institute Partners with UNCF to Recruit Students to Biomedical Research Careers 2Leaders in Science Join Upcoming Celebration of the 100th Anniversary of the Oldest Science Foundation in America 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 2Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 3Echo Therapeutics Announces Positive Results of Clinical Trial of its Symphony® Transdermal Continuous Glucose Monitoring (tCGM) System in Patients With Type 1 and Type 2 Diabetes 4
(Date:8/25/2015)... LAKE CITY and BELLEVUE, Wash. ... global leader in advanced robotic systems, announced today it ... robotic unmanned ground vehicle (UGV), at the National Tactical ... City.  The Guardian S is the ... the culmination of years of research and in-field trials ...
(Date:8/20/2015)... ., Aug. 20, 2015 NXT-ID, Inc. ... biometric authentication company focused on the growing mobile commerce ... it has joined The Smart Card Alliance and the ... Card Alliance and the Smart Card Alliance Latin America ... to industry peers and thought leaders promoting adoption of ...
(Date:8/12/2015)... 12, 2015   MedNet Solutions , an innovative ... of clinical research, is proud to announce that ... SaaS-based eClinical technology platform, has led the way to ... quarters of 2015.   Q2 2015 and Q1 2015 ... by contract value sold in the company,s 15 year ...
Breaking Biology News(10 mins):Sarcos to Debut First-of-its-Kind Snake Robot 2Sarcos to Debut First-of-its-Kind Snake Robot 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 2NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 3NXT-ID, Inc. Joins Smart Card Alliance and EMV Migration Forum 4MedNet Solutions Experiences Explosive Corporate Growth 2
... diverse potential applications include the development of ... coatings for medical implants, coatings for semiconductors, ... materials, microelectronics and responsive nanomaterials, and surface-sensitive ... The patented technology stems from the discovery ...
... have contended for millennia that burning incense is good ... is good for our brains too. In a new ... ), an international team of scientists, including researchers from ... describe how burning frankincense (resin from the Boswellia plant) ...
... First identified in 1899, y-larvae have been one of ... one has ever found an adult of these puzzling ... leading generations of marine zoologists to wonder just what ... in BioMed Centrals open access journal, BMC Biology, reports ...
Cached Biology News:Scripps Research Institute awarded patent for remarkable chemical technology 2Scripps Research Institute awarded patent for remarkable chemical technology 3Scripps Research Institute awarded patent for remarkable chemical technology 4Incense is psychoactive: Scientists identify the biology behind the ceremony 2Clue to mystery crustacean in parasite form 2
... Specificity: This antibody recognizes murine ... cross-react with other related IRF ... with murine IRF7 protein was ... of the 293T cells transfected ...
... PS603. Immunogen: Synthetic phosphopeptide ... the phosphorylated Ser603 residue of ... Specific for synapsin I when ... Reactivity: Rat (positive control: ...
MMP-20 Immunogen: Activated recombinant human MMP-2 Storage: -20 C, Avoid Freeze/Thaw Cycles...
karyopherin alpha2 (2G7)...
Biology Products: